Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - Here's What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $26.11, but opened at $25.00. Chugai Pharmaceutical shares last traded at $25.99, with a volume of 2,411 shares traded.

Chugai Pharmaceutical Price Performance

The company has a market cap of $86.52 billion, a PE ratio of 32.46 and a beta of 0.68. The stock has a 50 day simple moving average of $27.04 and a two-hundred day simple moving average of $24.15.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.19 EPS for the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. The firm had revenue of $1.89 billion during the quarter. As a group, equities analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.